Mark-David Levin

628 total citations
4 papers, 127 citations indexed

About

Mark-David Levin is a scholar working on Genetics, Oncology and Immunology. According to data from OpenAlex, Mark-David Levin has authored 4 papers receiving a total of 127 indexed citations (citations by other indexed papers that have themselves been cited), including 2 papers in Genetics, 2 papers in Oncology and 2 papers in Immunology. Recurrent topics in Mark-David Levin's work include Chronic Lymphocytic Leukemia Research (2 papers), CAR-T cell therapy research (1 paper) and Peptidase Inhibition and Analysis (1 paper). Mark-David Levin is often cited by papers focused on Chronic Lymphocytic Leukemia Research (2 papers), CAR-T cell therapy research (1 paper) and Peptidase Inhibition and Analysis (1 paper). Mark-David Levin collaborates with scholars based in Netherlands, Poland and Czechia. Mark-David Levin's co-authors include Christian H. Geisler, Jennifer L. Phillips, Stephanie Manson, Marinus H. J. van Oers, Mario Petrini, Ira Gupta, Vanessa C. Williams, Kazimierz Kuliczkowski, Sebastian Grosicki and Steen Lisby and has published in prestigious journals such as The Lancet Oncology, BMC Medical Informatics and Decision Making and Blood Advances.

In The Last Decade

Mark-David Levin

4 papers receiving 123 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark-David Levin Netherlands	3	82	69	50	44	35	4	127
Bella Biderman Russia	5	56 0.7×	48 0.7×	35 0.7×	23 0.5×	26 0.7×	46	115
Jeffrey P. Sharman United States	7	103 1.3×	94 1.4×	38 0.8×	49 1.1×	43 1.2×	21	165
Ayed O. Ayed United States	6	50 0.6×	37 0.5×	39 0.8×	41 0.9×	83 2.4×	11	153
Michalis Iskas Greece	7	90 1.1×	73 1.1×	70 1.4×	43 1.0×	55 1.6×	10	165
Angela Cuoghi Italy	3	72 0.9×	63 0.9×	27 0.5×	50 1.1×	28 0.8×	3	137
Lesley Ann Sutton Sweden	5	57 0.7×	43 0.6×	34 0.7×	27 0.6×	31 0.9×	8	113
Jeeyeon Baik United States	6	31 0.4×	73 1.1×	28 0.6×	76 1.7×	61 1.7×	18	151
JA Burger United States	3	96 1.2×	60 0.9×	96 1.9×	51 1.2×	113 3.2×	4	212
Pallavi Galera United States	6	33 0.4×	51 0.7×	55 1.1×	75 1.7×	53 1.5×	13	153
Naïs Prade France	5	37 0.5×	29 0.4×	62 1.2×	31 0.7×	42 1.2×	8	138

Countries citing papers authored by Mark-David Levin

Since Specialization

Citations

This map shows the geographic impact of Mark-David Levin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark-David Levin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark-David Levin more than expected).

Fields of papers citing papers by Mark-David Levin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark-David Levin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark-David Levin. The network helps show where Mark-David Levin may publish in the future.

Co-authorship network of co-authors of Mark-David Levin

This figure shows the co-authorship network connecting the top 25 collaborators of Mark-David Levin. A scholar is included among the top collaborators of Mark-David Levin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark-David Levin. Mark-David Levin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

4 of 4 papers shown

1.

Kip, Michelle M. A., et al.. (2020). Preventing overuse of laboratory diagnostics: a case study into diagnosing anaemia in Dutch general practice. BMC Medical Informatics and Decision Making. 20(1). 178–178. 1 indexed citations

2.

Kuiper, Rowan, Sonja Zweegman, Mark van Duin, et al.. (2020). Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial. Blood Advances. 4(24). 6298–6309. 22 indexed citations

3.

Hofland, Tom, Renate de Boer, Iris de Weerdt, et al.. (2019). Natural Killer Cell Hypo-responsiveness in Chronic Lymphocytic Leukemia can be Circumvented In Vitro by Adequate Activating Signaling. HemaSphere. 3(6). e308–e308. 20 indexed citations

4.

Oers, Marinus H. J. van, Kazimierz Kuliczkowski, Lukáš Smolej, et al.. (2015). Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology. 16(13). 1370–1379. 84 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact